179 related articles for article (PubMed ID: 17220638)
21. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
[TBL] [Abstract][Full Text] [Related]
22. The role of daily dialysis in the control of hyperphosphatemia.
Achinger SG; Ayus JC
Kidney Int Suppl; 2005 Jun; (95):S28-32. PubMed ID: 15882310
[TBL] [Abstract][Full Text] [Related]
23. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
24. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
[TBL] [Abstract][Full Text] [Related]
25. [A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis].
Borrego J; Pérez del Barrio P; Serrano P; García Cortés MJ; Sánchez Perales MC; Borrego FJ; Liébana A; Gil Cunquero JM; Pérez Bañasco V
Nefrologia; 2000; 20(4):348-54. PubMed ID: 11039260
[TBL] [Abstract][Full Text] [Related]
26. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?
Wang AY; Woo J; Sea MM; Law MC; Lui SF; Li PK
Am J Kidney Dis; 2004 Apr; 43(4):712-20. PubMed ID: 15042549
[TBL] [Abstract][Full Text] [Related]
27. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
[TBL] [Abstract][Full Text] [Related]
28. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease.
Block GA; Persky MS; Shamblin BM; Baltazar MF; Singh B; Sharma A; Pergola P; Smits G; Comelli MC
Nephron Clin Pract; 2013; 123(1-2):93-101. PubMed ID: 23797006
[TBL] [Abstract][Full Text] [Related]
29. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
Chudek J; Piecha G; Kokot F; Wiecek A
J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
[TBL] [Abstract][Full Text] [Related]
30. [Management of hyperphosphatemia in patients with chronic kidney disease].
Savica V; Santoro D; Monardo P; Mallamace A; Bellinghieri G
G Ital Nefrol; 2009; 26 Suppl 46():58-61. PubMed ID: 19644820
[TBL] [Abstract][Full Text] [Related]
31. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel DM; Farmer B; Smits G; Chonchol M
J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
[TBL] [Abstract][Full Text] [Related]
32. Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach.
Novak JE; Szczech LA
Semin Dial; 2009; 22(1):56-63. PubMed ID: 19000107
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
34. [Acute hyperphosphatemia secondary to phosphate administration for bowel preparation].
Gutiérrez E; González E; Hernández E; Herrero JC; Manzanera MJ; García JA; Domínguez-Gil B; Praga M
Nefrologia; 2004; 24(3):283-7. PubMed ID: 15283320
[TBL] [Abstract][Full Text] [Related]
35. Methods of controlling hyperphosphatemia in patients with chronic renal failure.
Llach F; Nikakhtar B
Curr Opin Nephrol Hypertens; 1993 May; 2(3):365-71. PubMed ID: 7922196
[TBL] [Abstract][Full Text] [Related]
36. Calcium-based phosphate binders are appropriate in chronic renal failure.
Friedman EA
Clin J Am Soc Nephrol; 2006 Jul; 1(4):704-9. PubMed ID: 17699276
[TBL] [Abstract][Full Text] [Related]
37. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
[TBL] [Abstract][Full Text] [Related]
38. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia.
Cupisti A; D'Alessandro C; Baldi R; Barsotti G
J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782
[TBL] [Abstract][Full Text] [Related]
39. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran.
Mahdavi-Mazdeh M; Zamyadi M; Norouzi S; Heidary Rouchi A
Iran J Kidney Dis; 2007 Jul; 1(1):25-8. PubMed ID: 19357440
[TBL] [Abstract][Full Text] [Related]
40. Hyperphosphatemia in end-stage renal disease.
Indridason OS; Quarles LD
Adv Ren Replace Ther; 2002 Jul; 9(3):184-92. PubMed ID: 12203200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
